G
MRNA icon

Gainplan’s Moderna MRNA Stock Holding History

Gainplan’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$482K Buy
+2,501
New +$270K 0.19% 38
2021
Q3 		– Sell
-1,693
Closed -$403K – 68
2021
Q2 		$403K Buy
+1,693
New +$303K 0.16% 51

Other funds holding MRNA

DLA
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
BVL
Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
LAI
Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return
PFM
Patton Fund Management Dallas, Texas $389M AUM 65.14% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
GCA
Gallagher Capital Advisors Argyle, Texas $187M AUM 21.63% 1-Year Est. Return
NIM
Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return
BSCCG
Blue Sky Capital Consultants Group Poway, California $239M AUM 14.34% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Gainplan's MRNA Position: Q3 2026 in Review

Gainplan opened a new position in Moderna (MRNA) in Q3 2026: 2,501 shares worth $482K. The stake represents 0.19% of the portfolio and ranks #38 among its holdings. This is a return to the name: Gainplan previously reported a position in MRNA as recently as Q2 2021.

Gainplan first reported a position in MRNA in Q2 2021 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Gainplan held 2,501 shares of Moderna worth $482K as of Q3 2026.
  • Moderna was a new Gainplan position in Q3 2026.
  • Moderna made up 0.19% of Gainplan's portfolio in Q3 2026, its #38 holding.
  • Gainplan first reported a position in Moderna in Q2 2021 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Gainplan's 13F filing for Q3 2026, filed 9 Oct 2026.